@article{3115562,
    title = "Application of paclitaxel-eluting metal mesh stents within the pig
ureter: An experimental study",
    author = "Liatsikos, Evangelos N. and Karnabatidis, Dimitrios and Kagadis, George and C. and Rokkas, Kostantinos and Constantinides, Costas and Christeas, and Nikolaos and Flaris, Nikolaos and Voudoukis, Theodore and Scopa, and Chrisoula D. and Perimenis, Petros and Filos, Kriton S. and Nikiforidis, and George C. and Stolzenburg, Jens-Uwe and Siablis, Dimitrios",
    journal = "European urology oncology",
    year = "2007",
    volume = "51",
    number = "1",
    pages = "217-223",
    publisher = "ELSEVIER SCIENCE BV",
    doi = "10.1016/j.eururo.2006.05.054",
    keywords = "ureter; hyperplasia; paclitaxel; metal stents",
    abstract = "Objective: The purpose of the present study is to compare the standard
bare metal stents (BMS) with the Paclitaxel-Drug Eluting Stent (DES) in
the ureter of a pig model.
Materials and methods: We report on an experimental study with ten
female pigs weighing between 25 and 30 kg. The stents were randomly
placed in either the right or left ureter in each of 10 study animals,
for a total of 20 stented ureters. Ten ureters were stented with an
R-Stent (Orbus Medical Technologies, Hoevelaken Netherlands), and ten
with a Paclitaxel-Eluting Coronary Stent (Boston Scientific, Natick, MA,
USA). Patency was measured by radiograph of the nephrostomy tract,
intravenous urography and virtual endoscopy at 24 hours and 21 days
after the initial procedure, respectively.
Results: Free flow of urine through the stents into the bladder was
documented in all stented ureters 24 hours after stent insertion by
radiograph of the nephrostomy tract. At the 21 day follow-up
examination, 5 R-Stents were found to be completely occluded and two
partially stenosed, whereas no occluded stent was detected in the
Paclitaxel-DES group. Pathology examination of the stents at 21 days
follow-up showed that the obstructed R-Stents generated severe
inflammation with metaplasia of the urothelium. The Paclitaxel-Eluting
MS generated a mild inflammatory response within the ureteral lumen at
the site of the stent, without hindering ureteral patency. R-stents
proved to develop more hyperplasia compared to the Paclitaxel-Eluting
MS.
Conclusions: Paclitaxel-DES, when compared with the standard R-Stent
BMS, generated less inflammation and/or hyperplasia of the surrounding
tissues, thus maintaining ureteral patency. Long-term animal trials are
required to further validate our results. (c) 2006 European Association
of Urology. Published by Elsevier B.V. All rights reserved."
}